These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 22663995)
21. Treatment of acute antibody-mediated rejection using bortezomib: a case report. Sin YH; Kim YJ; Oh JS; Lee JH; Kim SM; Kim JK Nephrology (Carlton); 2015 Jul; 20 Suppl 2():86-9. PubMed ID: 26031595 [TBL] [Abstract][Full Text] [Related]
22. The excellent outcomes of ABO-incompatible kidney transplantation with high titer (>×2048) using anti-CD20 and anti-CD25 antibody without splenectomy: two case reports. Koshino K; Okamoto M; Sakai K; Suzuki T; Nobori S; Matsuyama M; Ushigome H; Okajima H; Yoshimura N Transplant Proc; 2011; 43(6):2379-82. PubMed ID: 21839272 [TBL] [Abstract][Full Text] [Related]
28. Poor graft outcome in recipients with de novo donor-specific anti-HLA antibodies after living related kidney transplantation. Li X; Ishida H; Yamaguchi Y; Tanabe K Transpl Int; 2008 Dec; 21(12):1145-52. PubMed ID: 18803618 [TBL] [Abstract][Full Text] [Related]
29. Long-term experience of plasmapheresis in antibody-mediated rejection in renal transplantation. Brown CM; Abraham KA; O'Kelly P; Conlon PJ; Walshe JJ Transplant Proc; 2009 Nov; 41(9):3690-2. PubMed ID: 19917368 [TBL] [Abstract][Full Text] [Related]
30. Living-donor liver transplantation at the University of Tokyo, 1996-2011: the impact of HLA matching and a positive crossmatch on long-term survival and tolerance. Waki K; Sugawara Y; Mizuta K; Fujita H; Kadowaki T; Kokudo N Clin Transpl; 2011; ():223-35. PubMed ID: 22755416 [TBL] [Abstract][Full Text] [Related]
31. Comparison of the acute rejection incidence rate in spousal donor transplantation before and after anti-CD20 antibody (rituximab) protocol as desensitization therapy. Hirai T; Ishida H; Toki D; Miyauchi Y; Kohei N; Iida S; Tokita D; Shimizu T; Shirakawa H; Omoto K; Tanabe K Ther Apher Dial; 2011 Feb; 15(1):89-97. PubMed ID: 21272258 [TBL] [Abstract][Full Text] [Related]
32. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients. Meng HL; Jin XB; Li XT; Wang HW; Lü JJ Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748 [TBL] [Abstract][Full Text] [Related]
33. The acceptable reactive crossmatch (ARC), post-transplant monitoring, and their impact on kidney transplantation: a single center experience. Leone JP; Bowers V; Baliga R; Sanders C; LeFor W; Becker D; Thompson D; Resto-Ruiz S; Lopez-Cepero M Clin Transpl; 2011; ():373-9. PubMed ID: 22755434 [TBL] [Abstract][Full Text] [Related]
34. Graft loss associated with late humoral rejection after renal transplantation. Sun Q; Li L Clin Transpl; 2006; ():521-5. PubMed ID: 18365417 [TBL] [Abstract][Full Text] [Related]
35. Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Morath C; Beimler J; Opelz G; Scherer S; Schmidt J; Macher-Goeppinger S; Klein K; Sommerer C; Schwenger V; Zeier M; Süsal C Transpl Int; 2012 May; 25(5):506-17. PubMed ID: 22372718 [TBL] [Abstract][Full Text] [Related]
37. The role of the altruistic unbalanced chain in exchange living donor renal transplantation: single-center experience. Ahn BK; Kwon OJ; Kang CM Transplant Proc; 2012 Jan; 44(1):17-21. PubMed ID: 22310567 [TBL] [Abstract][Full Text] [Related]